Tealwood Asset Management Inc. Invests $1.13 Million in Krystal Biotech, Inc. $KRYS

Key Points

• Tealwood Asset Management Inc. invested approximately $1.13 million in Krystal Biotech, acquiring 8,183 shares of stock during the second quarter.
• Institutional ownership of Krystal Biotech is significant, with hedge funds and other institutional investors owning 86.29% of the company.
• Krystal Biotech reported earnings of $1.29 per share for the last quarter, exceeding analysts' expectations of $1.08.

Tealwood Asset Management Inc. bought a new position in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor bought 8,183 shares of the company's stock, valued at approximately $1,125,000.

Several other institutional investors also recently bought and sold shares of the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Krystal Biotech by 173.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 575,506 shares of the company's stock valued at $103,764,000 after purchasing an additional 365,304 shares during the last quarter. Braidwell LP grew its position in Krystal Biotech by 99.9% during the 1st quarter. Braidwell LP now owns 400,744 shares of the company's stock valued at $72,254,000 after purchasing an additional 200,244 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in Krystal Biotech by 3.0% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 250,514 shares of the company's stock valued at $45,168,000 after purchasing an additional 7,344 shares during the last quarter. Nuveen LLC purchased a new stake in Krystal Biotech during the 1st quarter valued at about $42,223,000. Finally, Woodline Partners LP grew its position in Krystal Biotech by 0.4% during the 1st quarter. Woodline Partners LP now owns 222,043 shares of the company's stock valued at $40,034,000 after purchasing an additional 941 shares during the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Krystal Biotech

In other news, insider Suma Krishnan sold 13,435 shares of the stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $150.30, for a total value of $2,019,280.50. Following the transaction, the insider owned 1,443,276 shares in the company, valued at $216,924,382.80. This represents a 0.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last quarter, insiders have sold 49,800 shares of company stock valued at $7,487,943. 13.70% of the stock is owned by corporate insiders.

Krystal Biotech Stock Performance

KRYS opened at $176.75 on Tuesday. The stock has a market capitalization of $5.12 billion, a P/E ratio of 35.92 and a beta of 0.66. The company's 50-day simple moving average is $150.07 and its two-hundred day simple moving average is $151.16. Krystal Biotech, Inc. has a 52-week low of $122.80 and a 52-week high of $207.84.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The company reported $1.29 earnings per share for the quarter, topping the consensus estimate of $1.08 by $0.21. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%. The firm had revenue of $96.04 million for the quarter, compared to analysts' expectations of $95.42 million. Research analysts forecast that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently commented on KRYS. Citigroup reissued a "neutral" rating and set a $166.00 price objective (down from $176.00) on shares of Krystal Biotech in a research report on Tuesday, August 5th. HC Wainwright restated a "buy" rating and set a $240.00 target price on shares of Krystal Biotech in a research note on Monday, September 15th. Chardan Capital lowered their target price on shares of Krystal Biotech from $219.00 to $216.00 and set a "buy" rating on the stock in a research note on Friday, August 22nd. Finally, Bank of America lowered their target price on shares of Krystal Biotech from $193.00 to $192.00 and set a "buy" rating on the stock in a research note on Tuesday, July 22nd. Six research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $209.00.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

Want to see what other hedge funds are holding KRYS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.